Much work has recently focused upon the cellular involvement of the mesangium in glomerular inflammation and fibrosclerosis. A host of mediators of inflammation have been identified and their actions studied in mesangial cell cultures [1] . The recent identification of functional receptors for prostaglandins (PG) and thromboxane A2 (TxA2) in cultured glomerular mesangial cells [2, 3] has prompted us and others to examine the relevance of these arachidonate (AA) metabolites to mesangial pathophysiology. We investigated whether exogenous eicosanoids (that is, 20°C atoms unsaturated lipids), in addition to their contractile (PGF2, TxA2) or relaxant (PGE2, PGI2) effects on mesangial cells, affect protein synthesis and growth rates in culture. The implications of such effects would be severalfold. First, AA metabolism occurs in normal glomerular cells, both in culture and in vivo [4] . Binding of prostanoids to mesangial or neighboring glomerular cells may modulate their functional behavior. Leukocytes and platelets also express functional receptors for AA metabolites, and may hence be recruited by and respond to such diffusible mediators. Second, AA metabolism is enhanced by vasoconstrictors, cytokines and growth factors released at the site of inflammation [5, 6] . This may, in turn, regulate the activity of these primary agents on target cells. Unlike growth factors or cytokines, the release of prostanoids can occur within seconds of application of stimuli, not requiring protein synthesis. In turn, induction of key enzymes in the metabolism of AA has been described in cytokine-activated cells. Thus, long-term regulation of prostanoid biosynthesis can also occur during chronic exposure to inflammatory polypeptide mediators [6] . Third, pharmacologic manipulation of PG and TxA2 synthesis or binding to cellular targets is well established, unlike growth factors and cytokines, at present. Several agents can therefore be employed as tools for dissecting out the relative contribution of eicosanoids to primary events in the progression of renal injury, such as glomerular hypertrophy, hypercellularity, and fibrosclerosis.
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Results and discussion Mesangial cells of rat and human origin can be easily grown in monolayer culture from glornerular explants, provided that a sufficient amount (that is, > 10%) of fetal bovine serum (FBS) is added to the media [1] . Preliminary evaluation of the growth rates of FBS-stimulated cultures established that rat cells undergo a cycle of DNA synthesis/division every 36 to 48 © 1992 by the International Society of Nephrology hours, while human cells have a faster growth rate of approximately 24 hours [7, 8] . Withdrawal of FBS results in a rapid reduction of [3H]-thymidine ([3H]-TdR) or 5-bromo-2'-deoxyuridine/5-fluoro-2 '-deoxyuridine incorporation, reflecting arrest in the G0!G1 phase of the cell cycle. From here synthesis of DNA can be reinitiated by addition of FBS or purified mitogens, resulting in synchronous growth of the cells. We have assessed in parallel the effects of a stable ligand for the TxA2 receptor, the endoperoxide analogue U-46619, on mesangial cell protein synthesis and growth. Protein synthesis was assessed by means of incorporation of radiolabeled aminoacids into newly synthesized proteins.
[3H]-leucine (1 tCi/ml) or [35S]-methionine (15 sCi/ml) were used as tracers for total protein synthesis and incorporation into specific, sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE)-separated proteins, respectively. As shown in Figure lA , total protein synthesis of quiescent cells was significantly enhanced during 24 hour incubations with 10 n to 1 tM U-46619. Accordingly, [3H]-TdR (1 Ci/ml) incorporation into DNA was dose-dependently stimulated by U-46619, with maximal effects at 1 tM. The effects of U-46619 were prevented by a specific blocker of TxA2 receptors, SQ 27,427 [8] . Although far less potent than FBS or purified peptide growth factors at comparably high concentrations, the TxA2 analogue was indeed capable of initiating such cellular events as protein synthesis and DNA duplication, in the presence of insulin (5 g/ml) as the only added cofactor. On the other hand, the behavior of protein synthesis and DNA synthesis in cells stimulated with FBS in the presence of U-46619 was opposite, with a clear additive effect on protein synthesis, while FBS-stimulated growth was inhibited (Fig. 1B) . Cell count experiments reflected this pattern [8] . The observation is interesting, since it indicates that TxA2 may reduce the proliferative effects of serum, while inducing protein synthesis, that is, cellular hypertrophy and/or matrix deposition. In further studies, 1-and 2-D SDS-PAGE on [35S]-methionine-labeled cells showed that the effects of U-46619 on protein synthesis are highly selective, as indicated by specific stimulation of proteins of molecular wt 35 to 50 and 125 to 200 kD. On the contrary, the majority of membrane-associated, cytosolic or extracellularly released proteins were unaffected by treatment of quiescent cells for up to 24 hours (Fig. 2) . These observations are in agreement with the data by Klotman and associates, who described the specific induction of multiple mRNA transcripts for collagen type IV, fibronectin and laminin in human mesangial cells treated with U-46619 [9] . Downregulation of the receptors may in part occur because of release of the autologous ligand by the cells themselves [4] . The exogenous ligand may also have less affinity than the native, 43 unstable substance. Finally, it is conceivable that the concentrations of prostanoids reached at or nearby the site of release are sufficient to locally saturate the membrane receptors. Tissue 31 or circulating levels are of difficult appreciation for this class of bioactive lipids, since TxA2 and PG are continuously synthesized, have an extremely short life span, and inactive metabolites tend to accumulate in body fluids. Second, does PG and TxA2 synthesis by intrinsic mesangial cells play a regulatory role on cell function, at least in culture? The issue has been addressed by several investigators, sometimes with conflicting results. Studies in extrarenal fibroblasts or smooth muscle cells have assigned a major role to endogenous AA metabolites in the regulation of cellular cyclic nudeotide levels and cell growth. The mitogenic effect of interleukin-I on vascular smooth muscle cells was greatly enhanced by cyclooxygenase inhibition [11] . In contrast, indomethacin inhibited the cyclic AMP and proliferative response to plateletderived growth factor (PDGF) in 3T3 fibroblasts, implying a permissive role of PG-stimulated cyclic nucleotides in the growth of this cell type [12] . PG synthesis inhibition reversed the antiproliferative effects of endogenous PG production in rat mesangial cells [13] . A recent study demonstrated that indomethacin or ibuprofen potentiate the mitogenicity of interleukin-lf3 in rat mesangial cells, consistent with potent induction of cyclooxygenase. and hence AA metabolism by this cytokine [14] .
If endogenous PG were involved in negative modulation of mesangial proliferation, then application of exogenous PG should exert inhibitory effects on cell growth. This is indeed the case for most studies of vasodilator PG. Both PGE2 and PG 12,  in the form of the stable analogue, Iloprost, stimulate cAMP accumulation and inhibit serum-stimulated growth of rat and human cells [3, 7, 8, [13] [14] [15] . PGE2 was also found to inhibit proline uptake and total cell protein synthesis [15] . The effect on cell-associated proteins and extracellular matrix synthesis appear to be dissociated, since Homma, Ichikawa and Hoover found stimulation of intrinsic cell protein synthesis by PGE2, along with inhibition of matrix deposition [13] . Of interest, the effects of vasodilator eicosanoids on proliferating cells could be duplicated with the vasoconstrictor TxA2 mimetic, U-46619, which characteristically employs different signal transduction mechanisms, namely phospholipase C activation and elevation of [Ca2 ] [2, 8] . This suggests that all cyclooxygenase metabolites inhibit serum-stimulated DNA synthesis at steps distal of their apparent transmembrane signals, or that other intracellular mechanisms account for their actions in cultured cells. It should be noted that the apparent paradox of stimulation of proliferation of quiescent cells and inhibition of serum-stimulated growth by U-46619 is reminiscent of previous reports on the effects of PGEJ in vascular smooth muscle cells [16] .
Indeed, the importance of position in the cell cycle should be emphasized when analyzing the effects of prostanoids. For practical reasons, both the situation of quiescent cells and of proliferating cells are relevant to glomerular pathophysiology; while the majority of mesangial cells undergo a rather slow turnover under normal conditions [1] , during inflammation the release of growth factors and cytokines is likely to trigger proliferation of resident glomerular cells.
In conclusion, given the complex and interactive effects of eicosanoids, which per se have only weak mitogenic or antimitogenic activity, it is prudent to consider these agents as modulators of proliferation, and evaluate their relationship with other primary stimuli of cell growth. The relative importance of eicosanoids in normal and deranged proliferation of kidney cells, as well as the potential for pharmacological intervention, will only be appreciated after careful examination of all of these variables in vitro and in vivo.
